Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.626
EU - Europa 3.667
AS - Asia 1.011
SA - Sud America 16
AF - Africa 10
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.534
IT - Italia 974
DE - Germania 742
IE - Irlanda 601
SE - Svezia 522
CN - Cina 468
GB - Regno Unito 301
HK - Hong Kong 274
UA - Ucraina 94
AT - Austria 92
CA - Canada 91
NL - Olanda 74
TR - Turchia 73
IN - India 69
FI - Finlandia 63
RU - Federazione Russa 57
FR - Francia 56
VN - Vietnam 44
DK - Danimarca 42
SG - Singapore 25
BE - Belgio 16
MY - Malesia 16
BR - Brasile 9
KR - Corea 9
IL - Israele 7
JP - Giappone 6
PL - Polonia 6
CH - Svizzera 5
ES - Italia 5
RO - Romania 5
AU - Australia 4
CL - Cile 4
GH - Ghana 4
MM - Myanmar 4
PK - Pakistan 4
HU - Ungheria 3
IR - Iran 3
SC - Seychelles 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
EE - Estonia 1
EU - Europa 1
IQ - Iraq 1
LK - Sri Lanka 1
LT - Lituania 1
MX - Messico 1
PH - Filippine 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 12.339
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Frankfurt am Main 657
Fairfield 634
Dublin 581
Chandler 569
Woodbridge 486
Wilmington 469
Houston 376
Ashburn 303
New York 276
Milan 273
Hong Kong 268
Dearborn 252
Seattle 245
Princeton 214
Cambridge 211
Jacksonville 147
London 124
Lawrence 103
Altamura 101
Nanjing 96
Vienna 89
Shanghai 88
San Diego 70
Beijing 67
Chicago 55
Boardman 48
Rome 35
Andover 29
Lachine 29
Helsinki 27
Lissone 27
Toronto 27
Nanchang 24
Fremont 20
Monza 20
Pune 20
Ottawa 18
Hebei 17
Los Angeles 17
Guangzhou 16
Hangzhou 16
Penang 16
Brussels 15
Norwalk 15
Turin 15
Changsha 14
Genoa 14
Mountain View 14
Kunming 13
Mumbai 13
Tianjin 13
Falls Church 12
Jinan 12
Jiaxing 11
Bedford 10
Bologna 10
Shenyang 10
Bergamo 9
Detroit 9
Dong Ket 9
Edmonton 9
Kocaeli 9
Groningen 8
New Bedfont 8
Ningbo 8
Passignano sul Trasimeno 8
Buffalo 7
Council Bluffs 7
Munich 7
São Paulo 7
Bari 6
Central 6
Hefei 6
Kiev 6
Kilburn 6
Laurel 6
Padova 6
Paris 6
Tappahannock 6
Washington 6
Zanica 6
Carate Brianza 5
Castiglione del Lago 5
Floridia 5
Garbagnate Milanese 5
Haikou 5
Modena 5
Salerno 5
Sanluri 5
Singapore 5
Taiyuan 5
Terni 5
Zhengzhou 5
Accra 4
Appiano Gentile 4
Bonndorf 4
Castelnuovo Scrivia 4
Daejeon 4
Delhi 4
Totale 9.880
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 399
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 285
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 284
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 252
Autoimmune liver disease, autoimmunity and liver transplantation 246
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 234
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 212
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 200
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 192
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 185
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 182
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 182
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 178
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 172
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 169
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 168
Precision medicine in primary biliary cholangitis 167
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 163
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 162
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 159
The challenges of primary biliary cholangitis: What is new and what needs to be done 157
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 155
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 153
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 151
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 150
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 147
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 143
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 142
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 142
New Therapeutic Targets in Autoimmune Cholangiopathies 140
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 134
Leptin attenuates ischemia-reperfusion injury in the rat liver 133
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 133
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 129
Treatment of PBC-A step forward 123
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 123
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 122
Prognostic models in primary biliary cholangitis 122
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 119
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 117
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 115
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 115
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 114
Cell and organ bioengineering technology as applied to gastrointestinal diseases 114
Genetics and epigenetics of primary biliary cirrhosis 114
Treatment discontinuation with peg-interferon: What to consider 113
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 113
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 112
The immunobiology of female predominance in primary biliary cholangitis 111
Hepatitis C virus and nonliver solid organ transplantation 110
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 107
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 106
The application of artificial intelligence in hepatology: A systematic review 105
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 104
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 104
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 104
The "gut microbiota" hypothesis in primary sclerosing cholangitis 103
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 100
Calcium channel blockers or angiotensin-converting enzyme inhibitors for de novo hypertension after liver transplant: and the winner is …? 100
An unusual endoscopic finding in a patient with melena: multiple gastric ulcers of regular shape 100
Prevention of hepatitis C recurrence after liver transplantation: An update 98
Liver Transplantation in the Clinic - Progress Made During the Last Three Decades 97
Risk stratification in primary sclerosing cholangitis 97
The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study 96
Reply to: "Fatigue and liver transplantation in patients with primary biliary cirrhosis" 96
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 96
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 95
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 93
Cost of illness of Primary Biliary Cholangitis - a population-based study 93
Primary Biliary Cholangitis: advances in management and treatment of the disease 90
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 88
Toward precision medicine in primary biliary cholangitis 87
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 87
The epigenetics of PBC: The link between genetic susceptibility and environment 86
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 86
Endocrinology and Metabolic Diseases (Including Diabetes) 85
International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and UK 84
Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis 82
Risk stratification and prognostic modelling in primary biliary cholangitis 82
Solid organ transplantation: has the promise been kept and the needs met? Solid Organ Transplantation in the Regenerative Medicine Era 77
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid 76
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 76
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 72
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis 72
Management of patients with autoimmune liver disease during COVID-19 pandemic 71
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 71
Individualizing Care: Management Beyond Medical Therapy 69
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry 69
Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All 67
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 64
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists 63
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 63
Novel treatments targeting immune-related mechanisms in primary biliary cholangitis 62
Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis 60
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase 58
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 54
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 53
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 52
Autoimmune liver diseases 47
Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments 46
Totale 12.150
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019237 0 0 0 0 0 0 0 0 0 0 110 127
2019/20201.798 169 122 72 148 155 244 240 166 148 178 110 46
2020/20212.605 89 66 379 178 184 261 283 312 237 213 207 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.217 71 111 108 258 293 580 383 76 156 173 8 0
Totale 13.099